Selected article for: "case severe and critical case"
Author: Huijie Bian; Zhao-Hui Zheng; Ding Wei; Zheng Zhang; Wen-Zhen Kang; Chun-Qiu Hao; Ke Dong; Wen Kang; Jie-Lai Xia; Jin-Lin Miao; Rong-Hua Xie; Bin Wang; Xiu-Xuan Sun; Xiang-Min Yang; Peng Lin; Jie-Jie Geng; Ke Wang; Hong-Yong Cui; Kui Zhang; Xiao-Chun Chen; Hao Tang; Hong Du; Na Yao; Shuang-Shuang Liu; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Gang Nan; Qing-Yi Wang; Jian-Qi Lian; Zhi-Nan Chen; Ping Zhu
Title: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
  • Document date: 2020_3_24
    • ID: 6g34qwer_27
    Snippet: The case severity of severe and critical cases in both groups were improved significantly compared to baseline, since 7 days post-treatment (figure 2B). In particular, at day 28, 4 severe cases and 1 critical case were improved to common and no case was discharged in control group. In meplazumab group, 9 cases (6 severe and 3 critical) were discharged, 2 critical cases were improved to common, and 1 critical case was improved to severe, demonstra.....
    Document: The case severity of severe and critical cases in both groups were improved significantly compared to baseline, since 7 days post-treatment (figure 2B). In particular, at day 28, 4 severe cases and 1 critical case were improved to common and no case was discharged in control group. In meplazumab group, 9 cases (6 severe and 3 critical) were discharged, 2 critical cases were improved to common, and 1 critical case was improved to severe, demonstrating a significantly beneficial outcome compared to control group (p=0.021, table 2 and figure 2B ). These results indicated that meplazumab treatment accelerated the improvement and make a rapid recovery from COVID-19 pneumonia, especially for the severe and critical cases. In this trial, no death was reported in all patients.

    Search related documents:
    Co phrase search for related documents
    • baseline compare and patient report: 1
    • case severity and control group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • case severity and critical case: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • case severity and critical severe case: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • case severity and improvement accelerate: 1
    • case severity and meplazumab group: 1, 2, 3, 4, 5
    • case severity and meplazumab treatment: 1, 2, 3
    • case severity and severe case: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • common improve and control group: 1
    • common improve and severe improve: 1
    • control group and critical case: 1, 2, 3
    • control group and critical severe case: 1, 2, 3
    • control group and meplazumab group: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • control group and meplazumab treatment: 1, 2, 3, 4, 5, 6
    • control group and patient report: 1, 2, 3, 4, 5
    • control group and rapid recovery: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • control group and severe case: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • control group and severe improve: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • control group discharge and severe improve: 1